AASLD
The Liver Meeting®

INDUSTRY PROGRAMMING GUIDE

SATELLITE SYMPOSIA
Page 5

TLM THEATERS
Page 25

NOV. 5–9, 2026 • DENVER, CO
www.aasld.org/the-liver-meeting

2026

More Than Fat in the Liver: Understanding the Metabolic Impact of MASLD and MASH

Sunday,
November 8, 2026
1:30 PM - 2:00 PM MT

TLM Theater #1,
Exhibit Hall F

This program explores the risks associated with MASLD/MASH, why early screening for liver fibrosis is needed in at-risk patients like those with obesity, and why metabolic drivers should be addressed as part of MASH care.

Meet the Speakers



Leigh Perreault, MD, FACE, FACP

Professor of Medicine,
University of Colorado Anschutz Medical Campus

Aurora, CO



Naim Alkhouri, MD, FAASLD, DABOM

Chief Medical Officer,
Summit Clinical Research

Director, Clinical Research Institute of Ohio (CRIOH)

Cleveland, OH

Scan the QR code or visit **seeobesitythinkliver.com** to learn more!

MASH, metabolic dysfunction-associated steatohepatitis;
MASLD, metabolic dysfunction associated steatotic liver disease.

This event does not qualify for continuing medical education (CME) credit.

This information is intended for US healthcare professionals only.

Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT 06877

Copyright © 2026 Boehringer Ingelheim Pharmaceuticals, Inc.
All rights reserved. (09/26) EM-US-104866

Boehringer Ingelheim

Visit the

EXHIBITS

Hall DEF

Friday, Nov. 6
5 - 6:30 PM
Opening Reception in Exhibit Hall

Saturday, Nov. 7
9:30 AM - 5 PM

Sunday, Nov. 8
9:30 AM - 5 PM

Scan the QR code to view exhibitors and Exhibit Hall map

Medscape EDUCATION

CME/CNE/CPE

The Metabolic MASH-UP
What's New and What's Hot

SUNDAY, NOVEMBER 8, 2026 | 12:45 PM – 2:00 PM MT

REGISTRATION AND LUNCH: 12:30 PM | **PRESENTATION:** 12:45 PM

COLORADO CONVENTION CENTER, 700 14TH ST
DENVER, COLORADO | **ROOM:** FOUR SEASONS BALLROOM 1

HYBRID

CHAIR



Mazen Noureddin, MD, MHSc, FAASLD
Professor of Medicine
Houston Methodist Hospital
Houston, Texas,
United States

FACULTY



Anita Kohli, MD
Chief Clinical Research Officer
Arizona Liver Health/
Arizona Clinical Trials
Phoenix, Arizona,
United States



Jörn Schattenberg, MD
Director
Department of Internal Medicine II
Saarland University Medical Center
Homburg, Germany

AGENDA

Welcome and Introduction
Mazen Noureddin, MD, MHSc, FAASLD

MASH As a Spectrum of Disease
Anita Kohli, MD

What Is the New MASH Patient Profile
All Faculty

Trials Endpoints in MASH
Mazen Noureddin, MD, MHSc, FAASLD

Emerging MASH Therapies
Jörn M. Schattenberg, MD

Individualizing MASH Therapeutic Approaches
All Faculty

Audience Q&A

Conclusions
Mazen Noureddin, MD, MHSc, FAASLD



Register Now!

For more information and to register, visit:
www.medscape.org/symposium/mash-fibrosis-2026

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2026. THIS EVENT/FUNCTION IS PROVIDED BY MEDSCAPE AND SUPPORTED BY INVENTIVA. THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Supported by an independent educational grant from Inventiva.

Produced by Medscape LIVE!

SATELLITE SYMPOSIA

Listings current as of October 7, 2026. Please refer to mobile app for updates.

Thursday, Nov. 5

Cases of Confounding Cholestasis: Navigating the Diagnostic and Therapeutic Challenges of PFICs
12 - 1:30 PM
Colorado Convention Center, Four Seasons Ballroom 4
SUPPORTED BY: Ipsen
ORGANIZED BY: Clinical Care Options, LLC dba Decera Clinical Education in partnership with Progressive Familial Intrahepatic Cholestasis (PFIC) Network
CME: Maximum of 1.50 *AMA PRA Category 1 Credits™*

PRESENTERS: Naim Alkhouri, MD, FAASLD, DABON; Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD; James E. Squires, MD, MS

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) are rare, heritable cholestatic liver diseases. Typically recognized in pediatric settings, they can present across the lifespan and pose particular challenges in adults. This interactive, case-based symposium will improve clinicians' competence in recognizing, diagnosing, and managing PFIC and ALGS in adults.

LEARNING OBJECTIVES


- Assess for late-onset and adult-presenting genetic cholestatic disorders in patients with suspected mimics or established diagnoses that warrant reevaluation
- Apply an evidence-informed diagnostic framework that incorporates systematic use of genetic testing to evaluate subtype-specific presentations in patients with suspected PFIC or ALGS across the lifespan
- Devise individualized, evidence-informed treatment and symptom management strategies for adults with PFIC and ALGS
- Implement a multidisciplinary care plan that integrates long-term disease monitoring, transition of care planning, and family-centered genetic counseling for patients with PFIC and ALGS

Scan the QR code to register

Join the CLDF for an accredited lunch symposium!

NAVIGATING THE NUANCES OF PRURITUS:

AN EXPERT PANEL ON COMPLEX CASES IN PBC SYMPTOM MANAGEMENT



SUNDAY, NOVEMBER 8 | 2026

12:30–2:00 PM

Accredited Lunch Symposium

Arrive early to secure your seat!

COLORADO CONVENTION CENTER
FOUR SEASONS BALLROOM 4
LOWER LEVEL (LL)

Earn up to **1.25** *AMA PRA Category 1 Credits™!*

EXPERT FACULTY



MODERATOR

Steven L. Flamm, MD
Rush University Medical Center
Chicago, IL



Aparna Goel, MD
Stanford Health Care
Redwood City, CA



Gideon M. Hirschfield, FRCP, PhD
Toronto General Hospital
Toronto, Canada



Raj K. Vuppalanchi, MD
Indiana University School of Medicine
Indianapolis, IN

SPACE IS LIMITED.
REGISTER NOW
TO RESERVE YOUR SEAT!

SCAN TO REGISTER & VIEW ACCREDITATION INFORMATION

Jointly provided by the University of Cincinnati and the Chronic Liver Disease Foundation.

University of Cincinnati | CLDF Chronic Liver Disease Foundation

This activity is supported through an educational grant by Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A.

Presented for attendees of The Liver Meeting® 2026. This is not an official event/function of the American Association for the Study of Liver Diseases.

From Recognition to Resolution: A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

12 - 1:30 PM

Colorado Convention Center, Four Seasons Ballroom 1

SUPPORTED BY: Novo Nordisk

ORGANIZED BY: Voxmedia LLC

CME: Maximum of 1.50 *AMA PRA Category 1 Credits™*

PRESENTERS: Arun Sanyal, MD; Rohit Loomba, MD, MHSc; Mazen Noureddin, MD, MHSc; Mary Rinella, MD

Metabolic dysfunction-associated steatohepatitis (MASH), the progressive, inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), is an increasing cause of end-stage liver disease. The therapeutic landscape has transformed with FDA approvals of resmetirom and semaglutide; optimal agent selection is complex. FGF21 analogs are in clinical development. This program is designed for those who manage patients with MASH.

LEARNING OBJECTIVES

- Apply the AASLD-endorsed stepwise noninvasive testing (NIT) framework — including FIB-4, VCTE/ELF, and MRE — to identify patients with MASH and significant fibrosis (F2–F3) who are candidates for pharmacotherapy, and describe the role of liver biopsy in cases of diagnostic uncertainty
- Compare the mechanism of action, phase 3 clinical evidence, patient selection criteria, and monitoring requirements for resmetirom and semaglutide 2.4 mg/week in patients with noncirrhotic MASH and F2–F3 fibrosis, and apply this comparison to individualized treatment decisions based on patient comorbidity profile
- Characterize the FGF21 analog class — including efruxifermin and pegozafermin — by mechanism of action, phase 2 and phase 3 evidence to date, and current regulatory status, and describe the evidence supporting the investigational role of FGF21 analogs in patients with precirrhotic MASH and compensated cirrhosis due to MASH
- Formulate an evidence-based management plan for patients with compensated MASH cirrhosis, including surveillance priorities, appropriate use of approved therapies for comorbid conditions, and accurate patient communication regarding investigational treatment options

Scan the QR code to register

While attending The Liver Meeting® 2026
Join Us For A Satellite Symposium

From RECOGNITION *to* RESOLUTION:

A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

REGISTER ONLINE AT:
SYMPOSIAREG.COM/22614

Thursday, November 5, 2026

Lunch and Symposium:
12:00 PM – 1:30 PM MT

Colorado Convention Center

Four Seasons Ballroom 1
700 14th Street, Denver, Colorado

CHAIR:
Arun Sanyal, MD

FACULTY:
Rohit Loomba, MD, MHSc
Mazen Noureddin, MD, MHSc
Mary Rinella, MD



This program is sponsored by VOX media INTERNATIONAL

This activity is supported by an educational grant from Novo Nordisk Inc.

This event is provided by Voxmedia LLC and supported by Novo Nordisk. This is not an official event/function of the American Association for the Study of Liver Diseases.

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum — From Embolization-Eligible HCC to Advanced Biliary Tract Cancers
12 - 1:30 PM
Colorado Convention Center, Four Seasons Ballroom 2/3
SUPPORTED BY: AstraZeneca
ORGANIZED BY: Physicians' Education Resource, LLC (PER)
CME: Maximum of 1.50 *AMA PRA Category 1 Credits™*

PRESENTERS: Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc), FASCO; Amit Singal, MD, MS; Pierre Gholam, MD

Join the conversation at PER's hybrid CME satellite symposium! This interactive format will feature emerging clinical evidence via real patient cases and decision points, covering treatment selection and multidisciplinary strategies across the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) continuum.

LEARNING OBJECTIVES

- Assess the clinical significance of emerging data on immunotherapy-based combination regimens for patients with embolization-eligible and advanced unresectable HCC
- Develop individualized first-line treatment strategies for patients with HCC and BTC by applying data from recent phase 3 trials
- Develop a multidisciplinary framework for incorporating next-generation immunotherapy approaches into the hepatobiliary cancer treatment continuum

Scan the QR code to register

Download the mobile app for updates, and add these events to your schedule.

Metabolic Connections: Rethinking MASLD, MASH, and Obesity in an Evolving Management Landscape

6 - 8 PM

Hyatt Regency Denver, Centennial Ballroom E

SUPPORTED BY: Boehringer Ingelheim Pharmaceuticals, Inc.

ORGANIZED BY: Clinical Care Options, LLC dba Decera Clinical Education

CME: Maximum of 1.50 *AMA PRA Category 1 Credits™*

PRESENTERS: Arun B. Jesudian, MD; Kenneth Cusi, MD, FACP, FACE

Evidence increasingly highlights the overlapping prevalence and shared pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and other cardiometabolic conditions, yet the interconnected nature of these diseases is often underrecognized in patient care. Guideline-recommended screening for MASLD remains low among patients at increased risk, such as those with obesity, and many adults with MASLD are unaware of their condition. At the same time, rapidly evolving evidence, guidelines, and treatment options are expanding opportunities to address obesity and related conditions while creating new challenges for clinicians in providing integrated care. A clear understanding of the links among obesity, MASLD/MASH, and cardiometabolic disease, along with the role of treatments targeting weight loss in improving metabolic health, is essential for optimal patient care. Focusing on small-group, case-based discussions and real-time expert feedback, this symposium will equip healthcare professionals to consider underlying pathophysiology, apply screening and risk-stratification strategies, and translate emerging evidence into practice as they develop individualized, comprehensive care plans that support liver and overall cardiometabolic health.

LEARNING OBJECTIVES

- Analyze current evidence describing the interconnected metabolic pathways linking obesity, liver health, and cardiovascular risk.
- Implement recommended screening and risk assessments to improve timely detection of MASLD/MASH in patients at risk.
- Incorporate the latest efficacy and safety data for new and emerging treatments into integrated management decisions for patients with obesity and MASLD/MASH.

Scan the QR code to register

Friday, Nov. 6

Breaking News: A New Era for Noninvasive Tests to Detect Liver Fibrosis and Identify Patients for Novel Therapies
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 1
SUPPORTED BY: Siemens Healthineers
ORGANIZED BY: Medscape Education

CME: Maximum of 1.50 *AMA PRA Category 1 Credits™*

PRESENTERS: Taryn Winter Brill; Manal F. Abdelmalek, MD, MPH; Sonal Kumar, MD, MPH; Jörn Schattenberg, MD

We're tackling a rapidly evolving landscape of metabolic dysfunction associated steatohepatitis (MASH). With new therapies now available for noncirrhotic MASH with significant fibrosis, accurate patient stratification is essential. Noninvasive testing (NIT) has proven to be a highly accurate and practical tool for detecting significant liver fibrosis. This engaging session highlights the urgent unmet needs in MASH management and reviews the latest clinical data on breakthrough treatments. The live exchange between experts will dive into the practical, clinical utility of NITs for accurately assessing liver fibrosis.

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
Have increased knowledge regarding the
- Urgent need in metabolic dysfunction-associated steatohepatitis (MASH) management
- Clinical data on novel therapies for MASH
- Clinical utility of NITs in the management of at-risk MASH
- Demonstrate greater confidence in their ability to
- Use NITs appropriately in the management of at-risk MASH

Scan the QR code to register

The Latest ACLF Research, Ready to Share

Get access to new ACLF and PHT research and insights that have emerged since last spring. Hear directly from the researchers behind the work as they share findings that are now ready for discussion, collaboration, and application. Join AASLD at the 2027 Emerging Topic Conference, ACLF & Portal Hypertension: From Mechanism to Mastery.

Patient-Centered Care: Managing Primary Biliary Cholangitis in the Clinic
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 2/3
SUPPORTED BY: Ipsen
ORGANIZED BY: Medscape Education and PBC Foundation
CME: Maximum of 1.25 *AMA PRA Category 1 Credits™*

PRESENTERS: Mark G. Swain, MD, MSc, FRCP, FAASLD, FCAHS; Alan Bonder, MD, AGAF; Emma Culver, MBChB, DPhil, FRCP; Robert Mitchell-Thain

Unlock key insights and practical strategies in the management of primary biliary cholangitis (PBC) at this dynamic, case-based "Medscape Clinic style" symposium. Hear from expert faculty as they discuss the latest in PBC diagnosis, risk assessment, treatment selection, setting goals with patients, and other important topics. Through interactive discussions and real-world cases, you'll come away with a better understanding of comprehensive PBC management that you can apply to your own patients in the clinic. Don't miss this opportunity to advance your expertise and elevate outcomes for your patients with PBC.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:
Have greater competence related to
- Determining when to advance from first-line to second-line treatment in patients living with PBC
- Selecting second-line PBC therapies that improve symptoms and biochemical parameters

Demonstrate greater confidence in their ability to
- Recommend patient-centric PBC management strategies

Scan the QR code to register

See What's Happening Each Day

Quickly find when major programs, courses, and events are scheduled so you can plan your time with confidence.

Redefining Success: Individualizing HBV Care
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 4
SUPPORTED BY: Aligos Therapeutics
ORGANIZED BY: Clinical Care Options, LLC dba Decera Clinical Education
CME: Maximum of 1.50 *AMA PRA Category 1 Credits™*

PRESENTERS: Chari Cohen, DrPH, MPH; Mark Sulkowski, MD, FAASLD; Norah Terrault, MD, MPH

As emerging therapies expand the potential for a functional cure in chronic hepatitis B (HBV), this endpoint may be appropriate for some patients, but not all. This symposium will explore individualized treatment goals, including durable viral suppression, partial cure, and functional cure, and how patient characteristics and preferences guide treatment decisions.


LEARNING OBJECTIVES
- Outline key limitations of current antiviral therapy for HBV
- Create individualized HBV therapy goals based on patient factors
- Evaluate the current evidence on emerging HBV therapies and their potential role in advancing patient care

Scan the QR code to register



JOIN US FOR AN ALTIMMUNE-SPONSORED
DISEASE STATE PRODUCT THEATER

Navigating the Confluence of Metabolic Dysfunction, Alcohol Use, and Advanced Liver Disease



Saturday, November 7
12:45–1:30 PM

Colorado Convention Center
TLM Theater 3
Exhibit Hall F

OUR SPEAKERS WILL:

- Explore the advanced liver disease continuum and prognostic importance of fibrosis
- Review metabolic drivers and the role of alcohol in advanced liver disease progression
- Highlight patient-centered approaches to integrated AUD and ALD care



Mazen Noureddin, MD, MHSc
Houston Methodist Hospital
Houston, TX



Rohit Loomba, MD, MHSc
University of California at San Diego
La Jolla, CA



Jessica Mellinger, MD, MSc, MPhil, MSt
Henry Ford Health – Michigan State University
Detroit, MI

altimmune

Saturday, Nov. 7

Breaking News in Primary Sclerosing Cholangitis: Bridging Gaps in Care
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 1
SUPPORTED BY: Mirum Pharmaceuticals
ORGANIZED BY: Medscape Education
CME: Maximum of 1.25 *AMA PRA Category 1 Credits™*

PRESENTERS: Taryn Winter Brill; Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD; Deepak Joshi, PhD, FRCP; Sonal Kumar, MD, MPH; Mark Chatterley, Patient Advocate with PSC Support

Primary sclerosing cholangitis (PSC) is a rare, progressive chronic liver disease, often associated with inflammatory bowel disease, that can lead to severe liver damage, cirrhosis, and liver failure if left untreated. This engaging, newsroom-style live symposium will feature expert faculty who will discuss the latest clinical evidence and best practices for diagnosing and managing PSC and its related complications. This dynamic event will feature a professional host, a patient testimonial, and plenty of time to interact with and ask questions of the faculty, who are leaders in the field. Attendees will come away with an in-depth understanding of PSC diagnosis and management, including the latest information on emerging therapies in clinical trials. Join us for Breaking News in PSC, and learn from the best!

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
Have increased knowledge regarding the
- Burden and consequences of primary sclerosing cholangitis (PSC)
- Clinical data on emerging PSC therapies

Have greater competence related to
- Implementing guideline-based diagnostic and surveillance tests into practice for patients with suspected or confirmed PSC

Demonstrate greater confidence in their ability to
- Design PSC treatment strategies that incorporate shared decision-making with patients

Scan the QR code to register



CHD may be hiding in plain sight.
It's time to build awareness.

Join the Conversation

WHEN?
Sunday, November 8, 2026
10:00-10:45 AM MST

WHERE?
Colorado Convention Center
Exhibit Hall F | Theater 3

Breakfast will be available

Featuring



Dr. Tatyana Kushner, MD, MSCE
Key Hepatology Opinion Leader



Dr. Robert Gish, MD
Key Hepatology Opinion Leader



Darlene Jubah
CHD Advocate

Building Awareness; Bridging to Action

Through key opinion leader perspectives and a conversation with an individual living with CHD, explore:

- Why CHD is still being missed and the impact of delayed identification
- The patient journey and opportunities to shift the identification paradigm
- An evolving treatment landscape and why identification matters now
- Your role in CHD care and actionable steps to advance identification and management

Make CHD part of the conversation.
Join us and help move CHD from rarely to routinely considered.

CHD: Chronic Hepatitis Delta.
Written and produced by Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. © 2026. All rights reserved.
US-NON-2600081, August 2026

mirum

Paving the Way to a Functional Cure for Hepatitis B
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 2/3
SUPPORTED BY: GSK
ORGANIZED BY: PRIME Education, LLC
CME: Maximum of 1.25 *AMA PRA Category 1 Credits™*

PRESENTERS: Mark S. Sulkowski, MD; Su H. Wang, MD, MPH, FACP; Yasmin Ibrahim, MD, PhD; Michael R. Stinchon, Jr, RPh

With a functional hepatitis B (HBV) cure on the horizon, providers must prepare for changing therapeutic guidelines. Join Hepatitis B Foundation experts, Drs. Su Wang, Mark Sulkowski, and Yasmin Ibrahim in person or via livestream on Nov. 7 for an interactive symposium on the latest hep B treatment updates.

LEARNING OBJECTIVES

- Assess current HBV treatment and monitoring recommendations and identify unmet needs in care
- Define a functional cure in chronic HBV and assess novel mechanisms to disrupt the viral life cycle
- Apply shared decision-making frameworks to help people with chronic HBV explore treatment options in the context of their own goals and preferences and support continuity of care

Scan the QR code to register

Claiming CME for The Liver Meeting 2026

CME credit claiming for The Liver Meeting 2026 will open on Thursday, November 5, 2026. For information on how to claim credits, visit the conference app.

Where Liver Meets Lung: Coordinating Modern AATD Care
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 4
SUPPORTED BY: Takeda Pharmaceuticals U.S.A., Inc.
ORGANIZED BY: Answers in CME
CME: Maximum of 1.0 *AMA PRA Category 1 Credits™*

PRESENTERS: Virginia Clark, MD, MS; Raj Vuppalanchi, MD; Brooks Thomas Kuhn, MD, MAS

Join leading alpha-1 antitrypsin deficiency (AATD) experts while attending The Liver Meeting® 2026! This activity will equip clinicians with tools to improve care for patients with AATD-associated liver disease. Learn about diagnosis and the clinical profiles of emerging therapies. Gain insight on coordinating care and then join the live Q&A!

LEARNING OBJECTIVES
- Outline how to facilitate a timely diagnosis of AATD
- Identify patients at risk for AATD-associated liver disease
- Review the clinical profiles of emerging therapies
- Propose patient-centered, multidisciplinary strategies to optimize the long-term management of patients with AATD-associated liver disease

Scan the QR code to register



Sunday, Nov. 8

From Uncertainty to Accuracy: Optimizing Outcomes in Adult Genetic Cholestatic Liver Diseases
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 2/3
SUPPORTED BY: Mirum Pharmaceuticals
ORGANIZED BY: Medscape Education
CME: Maximum of 1.25 *AMA PRA Category 1 Credits™*

PRESENTERS: Richard J. Thompson, MD; Silvia Vilarinho, MD, PhD; Mitchell L. Shiffman, MD

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) frequently present diagnostic challenges in adult clinical practice due to late-onset manifestations and overlapping systemic features. Key focus areas include diagnostic evaluation strategies to recognize adult-onset disease, characterization of hepatic and extrahepatic complications, and implementation of coordinated interprofessional care models. Additionally, evidence-based approaches for selecting targeted management strategies address bile acid accumulation, severe pruritus, and long-term hepatic outcomes. Interactive case-based analysis illustrates essential decision points to optimize clinical recognition, disease monitoring, and overall patient management.

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
- Evaluate and diagnose adult patients with suspected PFIC or ALGS
- Characterize the multisystemic nature of PFIC and ALGS and the need for coordinated interprofessional care
- Develop strategies for the appropriate use of targeted therapies in adult genetic cholestatic liver disease
- Build effective interprofessional care models for adult PFIC and ALGS

Scan the QR code to register

THE EVOLVING TREATMENT LANDSCAPE FOR ADULTS WITH MASH:

Results from a Phase 3 Trial[a]

Novo Nordisk invites you to join our expert faculty and your colleagues for this sponsored educational program.



Faculty
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Summit Clinical Research
Medical Director of Research and Director of the Steatotic Liver Program
Clinical Research Institute of Ohio
Westlake, OH

Saturday
November 7, 2026
Time: 1:30 PM – 2:00 PM MT
Refreshments will be provided[b]

TLM Theater #2
Exhibit Hall F
Colorado Convention Center
Denver, CO

Plan to arrive early to reserve your seat. Space is limited. Attendance is limited to full-access attendees only.

Program Description

Join us for a focused look at clinical data from a phase 3 trial, detailing the 72-week efficacy and safety of a treatment for adults with noncirrhotic MASH and moderate to advanced fibrosis. The session will outline how these results may support care for appropriate patients with this chronic liver disease.

This program is sponsored by Novo Nordisk. The faculty will be compensated for their participation in this program. This is a promotional education presentation; it will not be certified for continuing medical education credit.

[a]Presentation contains product-related education.
[b]Novo Nordisk will report all transfers of value, including meals, as required by law. Please refrain from consuming any meals available at this event if you are a health care provider licensed in a state that prohibits, or applies limits to, such interactions. Please contact NNI Ethics & Compliance with any questions at NNIComplianceassist@NovoNordisk.com.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, Novo Nordisk will not provide alcohol at its programs, and attendance at this program is limited to health care professionals with an educational need to receive the information. Additionally, attendance by guests or spouses is not appropriate and cannot be accommodated.

The content of this Product Theater and opinions expressed by the presenters are those of the sponsor or presenters and not those of The Liver Meeting® 2026.

Refreshments and the content of the Product Theater are the sole responsibility of Novo Nordisk Inc.

NOVO and the Apis Bull Logo are trademarks owned by Novo Nordisk A/S.
© 2026 Novo Nordisk All rights reserved. US26SN00274 September 2026

novo

Navigating the Nuances of Pruritus: An Expert Panel on Complex Cases in PBC Symptom Management
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 4
SUPPORTED BY: Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A.
ORGANIZED BY: Chronic Liver Disease Foundation (CLDF)
CME: Maximum of 1.25 *AMA PRA Category 1 Credits™*
CME Provided By: University of Cincinnati

PRESENTERS: Steven L. Flamm, MD, FACG, FAASLD (moderator); Aparna Goel, MD; Gideon M. Hirschfield, FRCP, PhD; Raj K. Vuppalanchi, MD

This symposium offers expert perspectives and practical insights for navigating complex primary biliary cholangitis (PBC) pruritus cases and optimizing individualized patient care. Faculty will review challenging, real-world cases and examine nuanced clinical decision-making beyond first-line management, including differential diagnosis, available treatment options, and the interconnected burden of itch, fatigue, and quality of life.

LEARNING OBJECTIVES
- Identify the pillars of care in PBC with a focus on improving quality of life through symptom management
- Analyze different approaches to managing pruritus in PBC
- Discuss data on approved PBC agents and PBC symptom burden

Scan the QR code to register

AASLD & AASLD Foundation Booth

Located in lobby A, parallel to registration, test your knowledge and arm with play-to-win games for a chance to take home AASLD and AASLD Foundation giveaways! Prizes include a tech cleaning kit, humidifier, salad shaker, travel organizer, and more.

SHOW ME THE DATA®

Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

NOVEMBER 5, 2026

Colorado Convention Center
Denver, CO
Room: Four Seasons 2/3

Lunch & Registration: 11:30 AM–12:00 PM MST
Scientific Session: 12:00–1:30 PM MST

Program Chair



Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc) FASCO

Faculty Speakers



Amit Singal, MD, MS



Pierre Gholam, MD



Nicole Rich, MD

goto PER®.com

Presented for attendees of The Liver Meeting® 2026. This event/function is provided by Physicians' Education Resource®, LLC and supported by AstraZeneca. This is not an official event/function of the American Association for the Study of Liver Diseases.

The Metabolic MASH-UP: What's New and What's Hot
12:30 - 2 PM
Colorado Convention Center, Four Seasons Ballroom 1
SUPPORTED BY: Inventiva
ORGANIZED BY: Medscape Education
CME: Maximum of 1.25 *AMA PRA Category 1 Credits™*

PRESENTERS: Mazen Noureddin, MD, MHSc, FAASLD; Anita Kohli, MD; Jörn Schattenberg, MD

The rising tide of metabolic disease has triggered a concurrent epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Despite this growing clinical burden, critical gaps remain in clinical awareness regarding disease prevalence, long-term consequences, effective risk assessment, and evidence-based management. With multiple novel therapeutic agents rapidly advancing through clinical trials for MASH, it is essential for clinicians to stay updated on these emerging treatment paradigms. Join us in this live exchange with the experts in the field to: Interpret emerging clinical data regarding new and developmental therapies for MASH and develop individualized treatment strategies tailored to a patient's specific degree of liver fibrosis, steatosis, and concurrent metabolic comorbidities.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:
Have increased knowledge regarding the
- Pathophysiological spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) to MASH and its systemic cardiometabolic complications
- Therapeutic endpoints used in clinical trials and how emerging MASH therapies achieve histological clearance and fibrosis improvement

Have greater competence related to
- Identifying high-risk patient profiles using validated noninvasive assessment techniques in primary and specialty care settings
- Formulating individualized, evidence-based treatment plans for MASH based on patient phenotypes, comorbid conditions, and novel mechanism-of-action profiles

Scan the QR code to register

FGF21 ANALOGS IN FOCUS:

From pathways to clinical evidence in MASH



Sunday, November 8, 2026

12:45–13:30 MST

Exhibit Hall F | Theater 3

Join Professor Arun J. Sanyal and Professor Kris Kowdley for a focused discussion on FGF21 analogs in MASH.
The faculty will explore current gaps in steatotic liver disease management, review the biological role and mechanism of action of FGF21, and examine clinical evidence and ongoing trials with FGF21 analogs.

FGF21 biology

Mechanisms in MASH

Clinical evidence

FACULTY



Prof. Arun J. Sanyal
Chair



Prof. Kris Kowdley
Speaker

FGF21, fibroblast growth factor 21; MASH, metabolic dysfunction-associated steatohepatitis.

TLM THEATERS

Listings current as of October 7, 2026. Please refer to mobile app for updates.

Saturday, Nov. 7

Advancing Treatment of Hepatitis Delta Virus in the United States
10 - 10:45 AM
Convention Center, Exhibit Hall F, TLM Theater 3
SUPPORTED BY: Gilead Liver Medical Affairs

Non-CME educational program for U.S. healthcare professionals reviewing hepatitis delta virus (HDV etiology, epidemiology, disease progression, screening/diagnosis, care-cascade gaps, and a hypothetical patient case, with an overview of bulevirtide as an FDA-approved treatment option for chronic HDV in eligible adults.

Supported by Gilead which provided funding. Gilead has had no input into the content of the materials used at this meeting/ conference.

PRESENTER: David Wyles, MD

Beyond Viral Suppression: Emerging Perspectives on Functional Cure in Chronic Hepatitis B
10 - 10:45 AM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: GSK Medical Affairs

Scientific advances are expanding the conversation around a functional cure and the future of chronic hepatitis B (CHB) management. Join expert faculty to review unmet needs in CHB management, gain insights on patient evaluation and monitoring, and explore emerging scientific developments in the CHB treatment landscape that may inform future clinical practice.

PRESENTERS: Norah Terrault, MD, MPH, FAASLD; Calvin Pan, MD, MACP, FAASLD, FACG; Jimyeong Son, AGPCNP-BC

This symposium is planned and provided by

pbc foundation support for life | Medscape EDUCATION

CME/CNE/CPE

Patient-Centered Care
Managing Primary Biliary Cholangitis in the Clinic

FRIDAY, NOVEMBER 6, 2026 | 12:45 PM – 2:00 PM MT

REGISTRATION AND LUNCH: 12:30 PM | **PRESENTATION:** 12:45 PM

COLORADO CONVENTION CENTER, 700 14TH ST
DENVER, COLORADO | **ROOM:** FOUR SEASONS BALLROOM 2/3

HYBRID

MODERATOR



Mark G. Swain, MD, MSc, FRCP, FAASLD, FCAHS
Cumming School of Medicine
University of Calgary
Calgary, Alberta, Canada

PANELISTS



Alan Bonder, MD, AGAF
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts, United States



Emma Culver, MBChB, DPhil, FRCP
John Radcliffe Hospital
Oxford, United Kingdom



Robert Mitchell-Thain
CEO
PBC Foundation

AGENDA


Welcome and Introductions
Mark G. Swain, MD, MSc, FRCP, FAASLD, FCAHS

PBC Risk Assessment – When to Move Beyond First-Line Therapy
Alan Bonder, MD, AGAF

Best Practices in Patient-Centric PBC Management
Robert Mitchell-Thain

Individualizing PBC Treatment – Updates and Insights
Emma Culver, MBChB, DPhil, FRCP

Concluding Remarks and Audience Q&A
All Faculty



REGISTER

Register Now!

For more information and to register, visit:
www.medscape.org/symposium/mash-fibrosis-2026

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2026. THIS EVENT/FUNCTION IS PROVIDED BY MEDSCAPE EDUCATION AND THE PBC FOUNDATION AND SUPPORTED BY IPSEN. THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Supported by an independent educational grant from Ipsen.

Produced by Medscape LIVE!

Evolving Approach to Second-Line Treatment in PBC: A Case-Based Discussion
10 - 10:45 AM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Ipsen

This session will highlight evolving approaches to second-line treatment in Primary Biliary Cholangitis (PBC) through a case-based discussion. It will provide practical insights and foster a dynamic exchange between leading hepatologists.

PRESENTERS: Maliha Ahmad, MD; Sammy Saab, MD, MPH, AGAF

Advancing Management of Chronic Hepatitis B
12:30 - 1 PM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: GlaxoSmithKline, LLC

Join us as we explore the changing chronic hepatitis B landscape, with a focus on how emerging approaches to disease evaluation can optimize patient outcomes. This session will examine evolving concepts in comprehensive assessment that may influence testing and treatment decisions.

PRESENTER: Robert S. Brown, MD, MPH, FAASLD

Pediatric Cholestasis: From Diagnosis to Long-Term Care
12:30 - 1 PM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Ipsen

Join Dr. Binita Kamath and Dr. Cara Mack on a journey from diagnosis to long-term management in pediatric cholestatic liver diseases. This session will explore early diagnosis, nutritional support, multidisciplinary care, prognostic biomarkers, and strategies for patient management.

PRESENTERS: Binita M. Kamath, MBBChir, FAASLD; Cara L. Mack, MD, FAASLD

BEYOND TIRED

SATURDAY
NOV 7
2026

5:00 -7:00 pm MT
The Maven Hotel

RSVP

Attend the live premiere of Beyond Tired

A never-before-seen look into life with PBC



Dr. Nadege Gunn











L. Marie
Person with PBC

People featured have been compensated by Ipsen for their time.

Brought to you by IPSEN

ALP +me

SUNDAY
NOV 8
2026


3:30–4:15 pm MT
Theater 2

Daily life informing management of PBC

What can patients living with primary biliary cholangitis (PBC) teach us about how they successfully manage the condition? Hear expert and patient perspectives on practical ways to recognize, assess and monitor PBC symptoms to better inform patient-centered care.



Dr. Aparna Goel
Stanford Medicine



Dr. Ashwini Mehta
Methodist Dallas Medical Center



Brenda
Living with PBC

This is an educational program sponsored by Ipsen Biopharmaceuticals, Inc. and is not a continuing medical education (CME) program. Dr. Goel, Dr. Mehta and Brenda have been compensated by Ipsen for their time.

©2026 Ipsen Biopharmaceuticals, Inc. All rights reserved. September 2026 NON-US-004865

Navigating the Confluence of Metabolic Dysfunction, Alcohol Use, and Advanced Liver Disease
12:45 - 1:30 PM
Convention Center, Exhibit Hall F, TLM Theater 3
SUPPORTED BY: Altimmune

Through interactive expert discussion, Drs. Noureddin, Loomba, and Mellinger will explore the advanced liver disease continuum and prognostic importance of fibrosis, review metabolic drivers and the role of alcohol in advanced liver disease progression, and highlight patient-centered approaches to integrated AUD and ALD care.

PRESENTERS: Mazen Noureddin, MD, MHSc; Rohit Loomba, MD, MHSc, FAASLD; Jessica L. Mellinger, MD

The Evolving Treatment Landscape for Adults With MASH: Results From a Phase 3 Trial
1:30 - 2 PM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Novo Nordisk, Inc.

Join us for a focused look at clinical data from a phase 3 trial, detailing the 72-week efficacy and safety of a treatment for adults with noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) and moderate to advanced fibrosis. The session will outline how these results may support care for appropriate patients with this chronic liver disease.

PRESENTER: Naim Alkhouri, MD, FAASLD

Understanding Unexplained Cholestasis: Connecting Genetic Insights to Clinical Care With a Real Patient Story
1:30 - 2 PM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: Mirum Pharmaceuticals

Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders associated with the accumulation of toxic bile acids and progressive liver injury. In this presentation, hear an adult patient share their experience living with PFIC, while Dr. Saab reviews the signs/symptoms, the role of genetic testing in diagnosis, and treatment considerations for adults with PFIC.

PRESENTERS: Sammy Saab, MD, MPH, AGAF, FACG, FAASLD; Stuart Johnson, adult patient living with PFIC

Medscape EDUCATION

CME

NEWS REPORT

Breaking News

A New Era for Non-Invasive Tests to Detect Liver Fibrosis & Identify Patients for Novel Therapies

FRIDAY, NOVEMBER 6, 2026 | 12:30 PM – 2:00 PM MT

REGISTRATION AND LUNCH: 12:15 PM | **PRESENTATION:** 12:30 PM

COLORADO CONVENTION CENTER, 700 14TH ST
DENVER, COLORADO | **ROOM:** FOUR SEASONS BALLROOM 1

HYBRID

HOST



Taryn Winter Brill
Medical Journalist

CHAIR



Manal F. Abdelmalek, MD, MPH
Professor of Medicine
Mayo Clinic
Rochester, Minnesota, United States

FACULTY



Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York, United States



Jörn Schattenberg, MD
Director Department of Internal Medicine II
Saarland University Medical Center
Homburg, Germany

AGENDA

News Desk Opening

On-the-Ground Reporting – The Unmet Need

Breaking News – A New Era for NITs to Detect Liver Fibrosis and Identify Patients for Therapy

Expert Panel Discussion – A Call to Action: What Clinicians Need to Do Now

Live Audience Q&A

Summary and Conclusions

Register Now!

For more information and to register, visit:
www.medscape.org/sympo/nits-in-mash

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2026. THIS EVENT/FUNCTION IS PROVIDED BY MEDSCAPE AND SUPPORTED BY INVENTIVA. THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Supported by an independent educational grant from Siemens Healthineers.

Produced by Medscape LIVE!

Clinical Insights Into a First-in-Class Treatment for Primary Biliary Cholangitis (PBC)
3:30 - 4:15 PM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Gilead Sciences, Inc.

Join us for a Product Theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.

PRESENTER: Eric J. Lawitz, MD, FAASLD

Rethinking MASH: Integrating Systemic Risk With Liver-Centered Disease Mechanisms
3:30 - 4:15 PM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: Madrigal

MASLD arises within systemic metabolic dysfunction, but what determines progression to MASH and fibrosis within the liver? This program examines how hepatic metabolic adaptation can become maladaptive under persistent stress, triggering cellular injury, inflammatory signaling, and fibrogenesis that drive progressive liver disease.

PRESENTERS: Sonal Kumar, MD, MPH; Sammy Saab, MD, MPH, AGAF, FACG, FAASLD

The Pancreas, the Bile Duct, and Beyond: Management With the First FDA-Approved Treatment for IgG4-Related Disease
3:30 - 4:15 PM
Convention Center, Exhibit Hall F, TLM Theater 3
SUPPORTED BY: Amgen

Highlight expert perspectives on diagnosing IgG4-RD and its manifestations, including type 1 AIP and IgG4-related sclerosing cholangitis. Review Importance of assessing patients with IgG4-RD for extra-GI manifestations and highlight clinical trial data.

PRESENTER: Pierre M. Gholam, MD



TRANSFORM YOUR SKILLS WITH LIVER*LEARNING*®

Advance your liver education with over 100+ *ON-THE-GO* webinars and courses

For more information, visit Liverlearning.aasld.org

AASLD
EDUCATION

Sunday, Nov. 8

Hep D: From Rare to Aware
10 - 10:45 AM
Convention Center, Exhibit Hall F, TLM Theater 3
SUPPORTED BY: Mirum Pharmaceuticals

CHD remains underdiagnosed, with patient identification historically limited by therapeutic options. Yet, it's the most aggressive form of viral hepatitis, with the worst outcomes when untreated. Join an interactive session with leading hepatologists and a person living with CHD to explore the diagnostic journey, care gaps, and evolving treatment landscape.

PRESENTERS: Tatyana Kushner, MD, MSCE; Robert Gish, MD, FAASLD; Darlene Jubah, CHD Advocate

Medscape EDUCATION



Breaking News in Primary Sclerosing Cholangitis
Bridging Gaps in Care

NOVEMBER 7, 2026 | 12:45 PM MT | HYBRID
ROOM: FOUR SEASONS BALLROOM 1

TEST & TEACH

From Uncertainty to Accuracy
Optimizing Outcomes in Adult Genetic Cholestatic Liver Diseases

NOVEMBER 8, 2026 | 12:45 PM MT | HYBRID
ROOM: FOUR SEASONS BALLROOM 2/3

Supported by an independent educational grant from Mirum Pharmaceuticals.

Produced by Medscape LIVE!

Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome From Pediatrics to Adults: Genetics, Disease Recognition, and Clinical Management
10 – 10:45 AM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Ipsen

Through pediatric and adult perspectives, this program will review the genetics, diagnosis, and management of PFIC and Alagille syndrome, providing practical insights to support care across pediatrics and adults and helping clinicians navigate management considerations.

PRESENTERS: Pierre Gholam, MD, FAASLD; Saeed Mohammad, MD

Unlocking the Potential of a Liver-Directed Treatment
10 – 10:45 AM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: Madrigal

Unlocking the potential of a liver-directed treatment examines the first and only treatment for MASH with moderate to advanced fibrosis that activates THR-B.

PRESENTERS: Lance L. Stein, MD, FAASLD; Ashwini P. Mehta, DO



Presented for attendees of The Liver Meeting® 2026. This event/function is provided by Answers in CME and supported by Takeda.
This is not an official event/function of the American Association for the Study of Liver Diseases.
Answers in CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Please contact live@answersinchme.com for more information.
© 2018-2026, Answers in CME

Advancing Management Goals in Primary Biliary Cholangitis (PBC): Biochemical Control, Residual Risk, and Symptom Burden

12:30 - 1 PM

Convention Center, Exhibit Hall F, TLM Theater 2


SUPPORTED BY: Ipsen

This interactive case-based session explores the evolving management goals in primary biliary cholangitis (PBC), highlighting the limitations of traditional biochemical response thresholds and the importance of residual risk assessment. Through real-world patient scenarios, faculty will examine alkaline phosphatase normalization, symptom burden, and comprehensive management strategies.

PRESENTERS: Professor Mark Swain; Dr. Alan Bonder

The Park @ TLM Returns

Enjoy the new rock wall and hydration station to stay active, experience six Denver-inspired summit spaces for focused programming, and cheer on fellow attendees during the annual **TLM Pickleball Tournament.**



Enhance Your Hepatocellular Carcinoma (HCC) Risk Assessment with In Vitro Diagnostic Serum Biomarkers AFP-L3 and DCP

Please visit Fujifilm while attending The Liver Meeting®

Booth #1963

Learn more about Fujifilm's risk biomarkers for HCC.

*Data on file

Steatotic Liver Disease: Completing the Care Mosaic—From Missed Diagnosis to Better Outcomes
12:30 - 1 PM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: GSK

Steatotic liver disease represents a substantial clinical and public health burden. This program will examine the role of noninvasive tests in the identification and referral of patients, explore approaches to enhancing early intervention and review the evidence supporting fibrosis regression as a key objective to improve patient outcomes.

PRESENTER: Naim Alkhouri, MD, FAASLD

FGF21 Analogs in Focus: From Pathways to Clinical Evidence in MASH
12:45 - 1:30 PM
Convention Center, Exhibit Hall F, TLM Theater 3
SUPPORTED BY: Novo Nordisk

During this interactive session, Drs. Arun Sanyal and Kris Kowdley will be highlighting current gaps in the management of steatotic liver disease, reviewing the mechanisms of FGF21 analogs in MASH, and discussing the clinical evidence for FGF21 analogs in MASH management.

PRESENTERS: Arun Sanyal, MD, FAASLD; Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD

More Than Fat in the Liver: Understanding the Metabolic Impact of MASLD and MASH
1:30 - 2 PM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: Boehringer Ingelheim Pharmaceuticals, Inc.

This program explores the risks associated with MASLD/MASH, why early screening for liver fibrosis is needed in at-risk patients like those with obesity, and why metabolic drivers should be addressed as part of MASH care.

PRESENTERS: Naim Alkhouri, MD, FAASLD, DABOM; Leigh Perreault, MD, FACE, FACP

Peer-to-Peer Series on Wilson Disease: Unmet Needs in Wilson Disease, Strategies for Long-Term Management, and the Role of CUVRIOR
1:30 - 2 PM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Orphalan Inc.

Join us for an informative presentation on Wilson disease. This promotional peer-to-peer discussion will explore unmet needs in Wilson disease, strategies for long-term management, and the role of an approved treatment option.

PRESENTER: Robert Gish, MD, FAASLD

ALP +Me: Daily Life Informing Management of PBC
3:30 - 4:15 PM
Convention Center, Exhibit Hall F, TLM Theater 2
SUPPORTED BY: Ipsen

What can patients living with primary biliary cholangitis (PBC) teach us about how they successfully manage the condition? Hear expert and patient perspectives on practical ways to recognize, assess and monitor PBC symptoms to better inform patient-centered care.

PRESENTERS: Aparna Goel, MD; Ashwini P. Mehta, DO; Brenda, living with primary biliary cholangitis

---

MASH Matters: The Role of the Liver in Metabolic Health
3:30 - 4:15 PM
Convention Center, Exhibit Hall F, TLM Theater 1
SUPPORTED BY: Boehringer Ingelheim Pharmaceuticals, Inc.

Join our Boehringer Ingelheim-sponsored Product Theater to hear more about the role of the liver in metabolic dysfunction, including a discussion on the broader impact beyond the liver. Our esteemed panel will also highlight the latest in MASLD/MASH patient management and answer your questions.

PRESENTERS: Mazen Noureddin, MD, MHSc, FAASLD; Nadege Gunn, MD, CPI, DABOM, FAASLD; Michael G. Knight, MD, MSHP, FACP, DABOM

Small Diameter Stents Widen Options: Reconsidering When and Who to TIPS
3:30 - 4:15 PM
Convention Center, Exhibit Hall F, TLM Theater 3
SUPPORTED BY: W. L. Gore & Associates

Join transplant hepatologist Dr. Brett Fortune and interventional radiologist Dr. Bartley Thornburg as they share real-world experience and case studies using small diameter TIPS. Explore how stent options for patients with ascites and variceal bleeding are influencing patient selection, referral timing, complications like HE, and procedural outcomes.

PRESENTERS: Brett E. Fortune, MD, MS, FAASLD, FAST; Bartley Thornburg, MD





SUBMIT YOUR RESEARCH

AASLD journals feature the latest scientific research, practice guidelines, and more in hepatology and liver disease.

SUBMIT YOUR MANUSCRIPT TO AN AASLD JOURNAL TODAY







AASLD PUBLICATIONS

GSK

Advancing management of chronic hepatitis B

Join us as we explore the **changing** chronic hepatitis B **landscape** and **evolving concepts** in comprehensive assessment that may influence testing and **treatment decisions**.

Visit Booth 761

Join us

Saturday, November 7th | 12:30 PM–1:00 PM
TLM Theater 1 | Exhibit Hall F
Colorado Convention Center

Lunch will be provided.

This is a commercial presentation, not a scientific engagement.
This is a non-CME event and does not qualify for CME, CE, or OC.

Robert S. Brown, MD, MPH
Paid Consultant to GSK



Trademarks are the property of their respective owners.

©2026 GSK or licensor.
NPUS-HBUJRNA260005
October 2026
Produced in USA.